Aura Biosciences (Nasdaq: AURA) announced the pricing of an underwritten public offering to fund registration-enabling activities for its lead asset, bel-sar (AU-011), and to advance its clinical programs in early choroidal melanoma, while simultaneously unwinding the position of an existing institutional stockholder. The Boston, Massachusetts-based company expects to generate USD 260.3 million in gross proceeds before deducting underwriting discounts, commissions, and other offering expenses.
The offering comprises 39,591,000 shares of common stock priced at USD 6.00 per share, alongside pre-funded warrants to purchase up to 3,800,000 additional shares at an exercise price of USD 0.00001 per warrant, offered at USD 5.99999 each. Aura has also granted underwriters a 30-day option to purchase up to an additional 6,508,650 shares on the same terms. Of the net proceeds, USD 205.1 million will be directed toward clinical program advancement, registration-enabling activities for bel-sar, and general corporate purposes. The remaining proceeds will fund the repurchase of 6,922,870 shares from Matrix Capital Management Master Fund, LP at USD 5.64 per share, representing the entirety of Matrix's position in Aura common stock. The offering was expected to close on or about May 5, 2026, subject to customary closing conditions.
Company overview and pipeline
Aura Biosciences is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, focused on developing precision therapies for solid tumors with the goal of preserving organ function. Its lead candidate, bel-sar (AU-011), is a virus-like drug conjugate designed for the treatment of primary indeterminate lesions and small choroidal melanoma via suprachoroidal administration. The asset has progressed through Phase Ib/2 evaluation in choroidal melanoma, with a Phase II trial described in a 2022 Annals of Oncology publication. The press release indicates that proceeds will support registration-enabling activities for bel-sar, though no specific timeline for a regulatory submission or top-line data readout was disclosed in the available materials. Beyond ocular oncology, bel-sar has also entered a Phase I open-label study in non-muscle-invasive bladder cancer, as documented in a 2023 Journal of Clinical Oncology publication. The company previously entered into a licensing agreement with Clearside Biomedical covering intellectual property, regulatory data, and a full technology transfer to support Aura's investigational new drug filing, which strengthened the regulatory foundation for its ocular oncology programs. No additional pipeline assets or recent business development transactions beyond those described were identified in the available materials.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article